(Q36758436)

16 August 2017

1 reference

title

Molecular mechanisms of pancreatic cancer and potential targets of treatment (English)

1 reference

16 August 2017

1 reference

Johannes-Matthias Löhr

object named as

Matthias Löhr

3

0 references

author name string

Ursula Aho

1

1 reference

16 August 2017

Xia Zhao

2

1 reference

16 August 2017

Roland Andersson

4

1 reference

16 August 2017

publication date

1 March 2007

1 reference

Scandinavian Journal of Gastroenterology

16 August 2017

published in

1 reference

16 August 2017

volume

42

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

279-296

1 reference

16 August 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Alterations of cell signaling pathways in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

The genetics of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Hereditary factors in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Familial risk of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Predictors of pancreatic cancer mortality among a large cohort of United States adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Pancreatic cancer biology and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Inflammatory mechanisms contributing to pancreatic cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Cytokine production by CAPAN-1 and CAPAN-2 cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Role of inflammation in pancreatic carcinogenesis and the implications for future therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Cancer genes and the pathways they control

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Molecular mechanisms of pancreatic carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Genetics and biology of pancreatic ductal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Animal models of exocrine pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

A subclass of Ras proteins that regulate the degradation of IkappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Mutant KRAS in the initiation of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Tumour suppressor genes in disease and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Genetic abnormalities in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

DPC4/SMAD4 gene alterations in human cancer, and their functional implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Genetic progression in the pancreatic ducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

TGF-beta signaling and cancer: structural and functional consequences of mutations in Smads.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

TGFbeta signaling in growth control, cancer, and heritable disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Molecular aspects of pancreatic cancer and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

The Medical Management of Pancreatic Cancer: A Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Radiation sensitization by inhibition of activated Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Growth factors in pancreatic health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

The epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Growth factors and their receptors in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Epidermal growth factor receptors: critical mediators of multiple receptor pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Specificity within the EGF family/ErbB receptor family signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

The neurotrophic action and signalling of epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Epidermal growth factor mediates detachment from and invasion through collagen I and Matrigel in Capan-1 pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

TGF alpha transgenic mice. A model of pancreatic cancer development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Radiation therapy and tamoxifen: concurrent or sequential? That is the question

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Pancreatic cancer: basic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Transcriptional anti-angiogenesis therapy of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Molecular and biological properties of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Pathways for aberrant angiogenesis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Pancreatic cancer growth is inhibited by blockade of VEGF-RII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Expression of vascular endothelial growth factors A and C in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Prognostic significance of angiogenesis in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

21 January 2018

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Arachidonic acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Prostaglandin and thromboxane biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

The role of cyclooxygenases in inflammation, cancer, and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Cyclooxygenase-2 expression in human pancreatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Suppression of pancreatic cancer cell invasion by a cyclooxygenase-2-specific inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

COX-2 controversy: where are we and where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

The murky waters of the coxibs: a review of the current state of play

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Introduction - The coxib controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

The NF-kappa B and I kappa B proteins: new discoveries and insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Mechanism of activation and function of protein kinase B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Mechanisms and consequences of activation of protein kinase B/Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Synthesis and function of 3-phosphorylated inositol lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Overexpression of TGF-beta by infiltrated granulocytes correlates with the expression of collagen mRNA in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Multimodality approaches for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Matrix metalloproteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Molecular prognostic markers in pancreatic cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Development of gene therapy to target pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Endogenous tumor necrosis factor functions as a resistant factor against hyperthermic cytotoxicity in pancreatic carcinoma cells via enhancement of the heart shock element-binding activity of heart shock factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

Aspirin and the Risk of Colorectal Cancer in Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601106384

10.1080/00365520601106384

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference